CN104127464A - Ophthalmic Blumea balsamifera oil preparation and preparation method thereof - Google Patents
Ophthalmic Blumea balsamifera oil preparation and preparation method thereof Download PDFInfo
- Publication number
- CN104127464A CN104127464A CN201410335805.1A CN201410335805A CN104127464A CN 104127464 A CN104127464 A CN 104127464A CN 201410335805 A CN201410335805 A CN 201410335805A CN 104127464 A CN104127464 A CN 104127464A
- Authority
- CN
- China
- Prior art keywords
- sodium
- blumeae balsamiferae
- oleum blumeae
- ophthalmic
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention discloses an ophthalmic Blumea balsamifera oil preparation and a preparation method thereof. The ophthalmic preparation comprises eye drops, an eye ointment, an ophthalmic liposome and clathrate compound eye drops. The ophthalmic Blumea balsamifera oil preparation is prepared by adopting Blumea balsamifera oil as an active effective component and adding medicinal auxiliary materials for the ophthalmic preparation, and concretely comprises 0.15-1wt% of Blumea balsamifera oil, and the balance the auxiliary materials for the ophthalmic preparation. The ophthalmic preparation can effectively treat conjunctivitis, and tests prove that the ophthalmic preparation has the advantages of no irritable inflammation reaction, safe and stable use and definite therapeutic effects.
Description
Technical field
The present invention relates to a kind of Oleum Blumeae Balsamiferae ophthalmic preparation and preparation method thereof, belong to medical technical field.
Background technology
Conjunctivitis (conjunctivitis) is the commonly encountered diseases of ophthalmology, the general designation of the inflammatory reaction that to be conjunctival tissue occur in the effect of extraneous and body oneself factor.Because most of conjunctiva directly contacts with extraneous, therefore be easily subject to the stimulation of infectious (as antibacterial, virus and chlamydia etc.) and non-infectious factor (wound, chemical substance and physical factor etc.) in surrounding, and the blood vessel of conjunctiva and lymphoid tissue are abundant, self and extraneous antigen easily make its sensitization.
The medicine eye drop being used for the treatment of mostly at present is Western medicine preparation, as acute viral conjunctivitis, can put with steroid (can ground pine) collyrium, to alleviate the state of an illness; Bacterial conjunctivitis, available non-irritating irrigation is as 2% boric acid water or normal saline flushing conjunctival sac, and a local effective antibiotic ophthalmic liquid medicine frequently, is coated with Antibiotic Eye Ointment before sleeping.But Western medicine preparation has clinical response weak curative effect and has the shortcomings such as side reaction.Chinese medicine preparation is fewer eye drop aspect developing, but Chinese medicine has the advantages such as curative effect continues, easily eradicates, toxic and side effects is low, is that this this research worker adopts pure Chinese medicinal preparation---Oleum Blumeae Balsamiferae eye drop.
Herba Blumeae Balsamiferae is China's Guizhou minority nationality medication.That Compositae Herba Blumeae Balsamiferae belongs to Blumea balsamiferaDC, the triumphant Diangd vob of Miao Ethnomedicine name shelves nest bvid plant, medicinal is branch and leaf, twig root, another name: Balsamiferou Blumea Herb, Borneolum Syntheticum Chinese mugwort, family tradition Chinese mugwort, Herba Blumeae Balsamiferae, great Ai etc.There is the loose stagnated fire of logical all keys, the effects such as reducing swelling and alleviating pain.The sublimate that Oleum Blumeae Balsamiferae belongs to Herba Blumeae Balsamiferae leaf through expression separation and oil, be the auxiliary product that extracts natural Broneolum Syntheticum product, wherein contain L-Borneol, Camphora, volatile oil, oils and fats and other useful compositions, there is good bactericidal antiphlogistic effect.Current research shows, L-Borneol in Oleum Blumeae Balsamiferae has the effect of antibacterial pain relieving, staphylococcus aureus, Staphylococcus albus, viridans streptococci, Hemolytic streptococcus, streptococcus pneumoniae are had to inhibitory action, and Camphora has the effects such as antifungal, antipruritic pain relieving.
The medicine that at present existing Herba Blumeae Balsamiferae or Oleum Blumeae Balsamiferae are made is as pharynx health buccal tablet, JINHOUJIAN PENWUJI, the vertical refreshing buccal drop pills of pharynx, Fuxuekang granules etc., there is the pharmacological actions such as heat-clearing and toxic substances removing, reducing swelling and alleviating pain, anti-inflammation, evident in efficacy to oral inflammation and gynecological inflammation.But there is not yet the ophthalmic preparation product of Herba Blumeae Balsamiferae.
Summary of the invention
The object of the invention is to provide a kind of Oleum Blumeae Balsamiferae ophthalmic preparation for the treatment of conjunctivitis.
Oleum Blumeae Balsamiferae ophthalmic preparation of the present invention comprises ordinary eye drops, eye ointment, liposome, clathrate eye drop etc. for eye.
Technical scheme of the present invention is: the weight proportion of the raw material components of the Oleum Blumeae Balsamiferae ophthalmic preparation for the treatment of conjunctivitis is: Oleum Blumeae Balsamiferae 0.15～1%, all the other pharmaceutic adjuvants that are ophthalmic preparation.
The weight proportion of the raw material components of the Oleum Blumeae Balsamiferae ophthalmic preparation for the treatment of conjunctivitis is: Oleum Blumeae Balsamiferae 0.5%, all the other are adjuvant.
The various components of Oleum Blumeae Balsamiferae ophthalmic preparation of the present invention are as follows:
A, eye drop preparation:
B, eye Liposomal formulation:
C, eye ointment preparation:
D, eye inclusion compound eye drops:
Described cosolvent is one or more in Polyethylene Glycol, sodium benzoate, acetamide, hyaluronic acid sodium, carbomer, poloxamer, polyvinylpyrrolidone and sodium alginate.
Described pH adjusting agent is one or more of sodium hydroxide, organic amine and/or mineral acid and salt, organic acid and salt thereof, sodium carbonate, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate, boric acid, Borax.
Described isoosmotic adjusting agent is one or more in sodium oxide, glucose, sodium acetate, sodium carbonate, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate, boric acid, Borax, propylene glycol, glycerol mannitol.
Described antiseptic is one or more in benzalkonium bromide, ethyl hydroxybenzoate, ethyl hydroxybenzoate, phenethanol.
Described antioxidant is one or more in sodium sulfite, sodium sulfite and sodium pyrosulfite, sodium thiosulfate, disodiumedetate (EDTA), arabo-ascorbic acid and sodium salt thereof, thiourea.
Described eye pasting substrate is one or more in fatty alcohol, Yellow Vaselin, white vaseline, lanoline and white oil.
Described eye is one or more in lecithin, PHOSPHATIDYL ETHANOLAMINE (PE), fabaceous lecithin, cholesterol, cephalin, cholesterol acetyl fat, cupreol, natrii tauroglycocholas, Yolk lecithin, synthetic two palmityls-DL-α phosphatidylcholine (DPPC), synthetic phospholipid acyl silk amino acid (PS), phosphatidylinositols (PI), sphingomyelin (SPH), sphingo (DCP), two myristoyl lecithin (DMPC), stearmide (SA) with liposome membrane material.
The clathrate material of described clathrate eye drop is one or more of cyclodextrin (CD), beta-schardinger dextrin-(β-CD) and second-HP-β-CD (HP-β-CD).
Compared with prior art, Oleum Blumeae Balsamiferae ophthalmic preparation of the present invention, through the inflammatory reaction of experimental verification nonirritant, has good inhibitory action to conjunctivitis, bactericidal antiphlogistic function well, and there is good stability.
The specific embodiment:
The present invention is further illustrated with experimental example by the following examples.
Embodiment 1:
Prepare Oleum Blumeae Balsamiferae eye drop:
Get 10g poloxamer and add swelling in 600ml water for injection; Take in addition sodium oxide 2.5g, boric acid 12g, Borax 1.5g, ethyl hydroxybenzoate 0.3g, sodium sulfite 1g, EDTA1g, injects water 300ml, is stirred to dissolve, then adds Oleum Blumeae Balsamiferae 1.5g, stirs it is dissolved, and regulating pH value is 7.0; By add swelling completely in poloxamer solution containing the mixed solution of principal agent, add water to 1000ml, stir, 0.1% activated carbon filtration, then crosses 0.22 μ m microporous filter membrane fine straining, aseptic subpackaged in eye drop bottle, packs and get final product.
Embodiment 2:
Prepare Oleum Blumeae Balsamiferae eye drop:
Get 80g poloxamer and add swelling in 600ml water for injection; Take in addition sodium oxide 4g, sodium dihydrogen phosphate 1.5g, sodium hydrogen phosphate 7.5g, phenethanol 1g, sodium sulfite 1g, EDTA1g, injects water 300ml, is stirred to dissolve, then adds Oleum Blumeae Balsamiferae 10g, stirs it is dissolved, and regulating pH value is 6.0; By add swelling completely in poloxamer solution containing the mixed solution of principal agent, add water to 1000ml, stir, 0.05% activated carbon filtration, then crosses 0.22 μ m microporous filter membrane fine straining, aseptic subpackaged in eye drop bottle, packs and get final product.
Embodiment 3:
Prepare Oleum Blumeae Balsamiferae eye drop:
Get 40g poloxamer and add swelling in 600ml water for injection; Take in addition sodium oxide 3g, sodium dihydrogen phosphate 2g, sodium hydrogen phosphate 8.5g, benzalkonium bromide 1g, sodium sulfite 1g, EDTA1g, injects water 300ml, is stirred to dissolve, then adds Oleum Blumeae Balsamiferae 5g, stirs it is dissolved, and regulating pH value is 8.0; By add swelling completely in poloxamer solution containing the mixed solution of principal agent, add water to 1000ml, stir, 0.2% activated carbon filtration, then crosses 0.22 μ m microporous filter membrane fine straining, aseptic subpackaged in eye drop bottle, packs and get final product.
Embodiment 4:
Prepare Oleum Blumeae Balsamiferae eye ointment:
Yellow Vaselin 750g, anhydrous lanolin 100g are heated to 150 ℃ of fusings, are incubated and are cooled to 60 ℃ after 1 hour, be eye pasting substrate, standby; Separately get Oleum Blumeae Balsamiferae 10g, sodium benzoate 60g, with 50g liquid paraffin, grind well, equivalent incremental method is added in above-mentioned eye pasting substrate, add sterilizing Yellow Vaselin to total amount 1000g, and stir it is fully decomposed evenly, by 180 mesh sieves, sieve, cooling, subpackage, packs and get final product.
Embodiment 5:
Prepare Oleum Blumeae Balsamiferae eye ointment:
White vaseline 500g, anhydrous lanolin 100g, liquid paraffin 100g are heated to 150 ℃ of fusings, are incubated and are cooled to 60 ℃ after 1 hour, be eye pasting substrate, standby; Get 40g poloxamer and add swelling in 75ml water for injection, separately get Oleum Blumeae Balsamiferae 1.5g, add water for injection 25ml, with sodium bicarbonate, regulating pH value is 7.2, stirs it is uniformly dispersed; Then add swelling completely in poloxamer solution, add again ethyl hydroxybenzoate 3g, sodium sulfite 1g, be stirred to dissolve, above-mentioned solution, by 0.22 μ m filtering with microporous membrane, adds appropriate eye pasting substrate to be ground into fine and smooth pasty state, with equivalent incremental method, be added in above-mentioned eye pasting substrate to total amount 1000g again, and stir it is fully decomposed evenly, by 180 mesh sieves, sieve, cooling, subpackage, packs and get final product.
Embodiment 6:
Prepare Oleum Blumeae Balsamiferae liposome:
Get water for injection 400ml, add Oleum Blumeae Balsamiferae 1.5g, polyvinylpyrrolidone 10g, benzalkonium bromide 0.2g, sodium bicarbonate 45g, sodium sulfite 2.5g, stir and make its dissolving; Get phosphatidase 12 0g, cholesterol 5g, be dissolved in ether 50g, be stirred to dissolve; Above-mentioned two liquid are mixed, add water to total amount 1000g, mix, sonic oscillation 30 minutes, proceeds in thin film evaporation instrument, and evaporation ether is to most, and above-mentioned solution is by 0.22 μ m filtering with microporous membrane.Aseptic subpackaged, pack and get final product.
Embodiment 7:
Prepare Oleum Blumeae Balsamiferae liposome:
Get water for injection 250ml, add Oleum Blumeae Balsamiferae 10g, poloxamer 80g, nipagin ester 2.5g, sodium dihydrogen phosphate 1.65g, sodium hydrogen phosphate 33.7g, sodium sulfite 2.5g, stir and make its dissolving; Get phosphatidase 12 0g, cholesterol 5g, be dissolved in ether 50g, be stirred to dissolve; Above-mentioned two liquid are mixed, add water to total amount 1000ml, mix, sonic oscillation 30 minutes, proceeds in thin film evaporation instrument, and evaporation ether is to most, and above-mentioned solution is by 0.22 μ m filtering with microporous membrane; Aseptic subpackaged, pack and get final product.
Embodiment 8:
Prepare Oleum Blumeae Balsamiferae inclusion compound eye drops:
Get beta-schardinger dextrin-10g, add water for injection 750ml, heating makes to dissolve, and adds Oleum Blumeae Balsamiferae 1.5g, poloxamer 10g, stirs and makes its dissolving; Put ultrasonator ultrasonic 10 minutes, then add successively sodium chloride 4g, boric acid 8g, Borax 6g, ethyl hydroxybenzoate 2.5g, sodium sulfite 1g, be stirred to dissolve; With sodium carbonate, regulating pH is 6.5, adds water to total amount 1000g and mixes, and above-mentioned solution is by 0.22 μ m filtering with microporous membrane; Aseptic subpackaged, pack and get final product.
Embodiment 9:
Prepare Oleum Blumeae Balsamiferae inclusion compound eye drops:
Get beta-schardinger dextrin-10g, add water for injection 750ml, heating makes to dissolve, and adds Oleum Blumeae Balsamiferae 10g, sodium alginate 80g, stirs and makes its dissolving; Put ultrasonator ultrasonic 10 minutes, then add successively sodium chloride 4g, boric acid 8g, Borax 6g, benzalkonium bromide 10g, sodium sulfite 1g, be stirred to dissolve.With sodium carbonate, regulating pH is 6, adds water to total amount 1000ml and mixes, and above-mentioned solution is by 0.22 μ m filtering with microporous membrane; Aseptic subpackaged, pack and get final product.
Embodiment 10:
Prepare Oleum Blumeae Balsamiferae inclusion compound eye drops:
Get second-HP-β-CD 20g, add water for injection 750ml, heating makes to dissolve, and adds Oleum Blumeae Balsamiferae 6g, sodium benzoate 20g, stirs and makes its dissolving; Put ultrasonator ultrasonic 10 minutes, then add successively sodium chloride 4g, boric acid 8g, Borax 6g, ethyl hydroxybenzoate 0.2g, sodium sulfite 1g, be stirred to dissolve; With sodium carbonate, regulating pH is 8, adds water to total amount 1000ml and mixes, and above-mentioned solution is by 0.22 μ m filtering with microporous membrane; Aseptic subpackaged, pack and get final product.
By test, verify beneficial effect of the present invention below:
Test 1: the extracorporeal bacteria inhibitor test of Oleum Blumeae Balsamiferae eye drop (embodiment 3)
The preparation of bacteria suspension: first hemophilus influenza, staphylococcus aureus, streptococcus pneumoniae, escherichia coli, bacillus pyocyaneus, 6 kinds of lyophilizing bacterial strains of staphylococcus epidermidis are seeded to respectively in serum broth, cultivate 18h for 37 ℃, from each enrichment liquid, picking one encircles microbionation to 5mL serum broth respectively, 37 ℃ of 18h, centrifugal (2000r/min, 10min), supernatant discarded; With physiological saline solution washing, recentrifuge; Each pipe precipitation is diluted with physiological saline solution.Adopt turbidimetry to make 5 kinds of bacteria suspension concentration be 1 * 105CFU/mL, standby.
Diluted sample: adopt test tube serial dilution method, the Oleum Blumeae Balsamiferae eye drop sample that is 0.5% by mass percentage concentration is respectively diluted to 6 different dilution factors with serum broth, 1/2,1/3,1/4,1/5,1/8 and 1/16.
Microbionation: to pastille meat soup, inoculum concentration is 50 μ L/ pipes by the bacterial suspension inoculation than after turbid.Set up the positive, feminine gender and blank group, wherein positive control: not dosing, adds bacterium simultaneously; Negative control: add the ampicillin of 80 μ g/mL, add bacterium; Blank: dosing, does not add bacterium.
Bacteria cultivation results: cultivate after 24h in 37 ℃ of incubators, observe the situation of each bacterial growth.Least concentration with finer contained drug is defined as minimum inhibitory concentration (MIC).Each picking one ring meat soup from finer, streak inoculation is to not containing on the flat board of medicine respectively.Cultivate 24h for 37 ℃, observe and have or not bacterium colony to form to determine the minimum bactericidal concentration (MBC) of medicine.
The antibacterial action result of table 1 Oleum Blumeae Balsamiferae eye drop
From above bacteriostatic test, the antibacterial minimum effective dosage of the Oleum Blumeae Balsamiferae eye drop sample that mass percentage concentration is 0.5% is 1/4 dilution factor, and now sample concentration is 0.125%.
Test 2: the irritation test of Oleum Blumeae Balsamiferae ophthalmic preparation
Test specimen: the sample of preparing according to embodiment 2,4,7,9 methods, numbered samples 1-4; According to the preparation method of embodiment 1, wherein the weight of Oleum Blumeae Balsamiferae is 12g, 15g, prepares sample 5,6.
Test method: get 7 of 18-22g mices, be divided at random 7 groups.Sample 1-6 group (Oleum Blumeae Balsamiferae mass percentage concentration is respectively 1%, 1%, 1%, 1%, 1.2%, 1.5%) and blank group (distilled water), every 2h drips 1 time, each 2-3 drips, and observe animal activity situation, after 24h, with air tap inserting method, put to death mice and get nasopharynx part mucosa, with 10% formaldehyde, embathing and send pathological biopsy immediately.
Irritation test result: observe mice behavior, mucosa, matched group and medicine group inorganization morphological change, the Oleum Blumeae Balsamiferae eye drop nonirritant inflammatory reaction of result show sample 1-4.Sample 5 has light inflammation reaction, sample 6 to have obvious stimulation reaction, shows within the scope of the invention the respond well and nonirritant of sample, and scope is reasonable.
Test 3: the antiinflammatory test of Oleum Blumeae Balsamiferae ophthalmic preparation
By animal inflammatory model, observe the inhibitory action of Oleum Blumeae Balsamiferae eye drop to inflammation.
(1) impact of Oleum Blumeae Balsamiferae ophthalmic preparation on rat paw edema due to agar
The concentrated solution of the Oleum Blumeae Balsamiferae ophthalmic preparation that employing embodiment 1,5,6,8 prepares, makes each dosage group be 1.5mg/kg containing Herba Blumeae Balsamiferae oil mass; Select 50 of healthy Wister rats, body weight 130～190g, male and female are not limit, and divide at random physiology saline control group, 1 group of embodiment, 5 groups of embodiment, 6 groups of embodiment, 8 groups of embodiment.Before Yu Zhiyan, with medicine, repeatedly smear the following position of rat paw and joint.Every day 5 times, continuously 3d.After last administration, 30min causes inflammation at rat paw subcutaneous injection 1% agar solution 0.05mL, measures the change in volume causing below rat paw joint, scorching front and back.Subsequently respectively at 1,3,5,24h each survey 1 right hind ankle joint girth, record result, be calculated as follows swelling:
Swelling (%)=(cause scorching after girth-cause scorching before girth)/cause scorching before girth * 100%
The impact (x ± s) of table 3 Oleum Blumeae Balsamiferae eye drop on rat paw edema due to agar
Oleum Blumeae Balsamiferae ophthalmic preparation therapeutic effect is remarkable, with matched group comparison, and P<0.01, difference has statistical significance
(2) the swollen impact of Oleum Blumeae Balsamiferae eye drop (embodiment 1) xylol induced mice ear
The concentrated solution that adopts Oleum Blumeae Balsamiferae eye drop, is divided into 3 dosage groups.Select 48 of body weight 18～22g Kunming mouses, male and female are not limit, and are divided at random 4 groups, i.e. normal saline matched group, Oleum Blumeae Balsamiferae eye drop 1.5mg/kg group, Oleum Blumeae Balsamiferae eye drop 0.15mg/kg group, Oleum Blumeae Balsamiferae eye drop 0.015mg/kg group.Smear mice left and right ear every day 5 times, continuously 3d.30min after last administration, drips dimethylbenzene in mouse right ear, puts to death animal after 15min, and with 6mm card punch, along the punching of left and right auricle same area, both sides auricle is weighed respectively, usings two weight differences as swelling level index.The difference of comparative drug group and matched group.The result that affects that Oleum Blumeae Balsamiferae eye drop xylol induced mice ear is swollen is that mice both sides auricle is weighed respectively, using two weight differences as swelling level index, and by the difference of comparative drug group and matched group, obtain the antiinflammatory action that inhibitory rate of intumesce judges Oleum Blumeae Balsamiferae eye drop.Suppression ratio=(model group swelling average-medication group swelling average)/model group swelling average * 100%.
The swollen impact of table 4 Oleum Blumeae Balsamiferae eye drop xylol induced mice ear
| Group | Dosage (mg/kg) | Number of animals (only) | Swelling (mg) | Suppression ratio % |
| Normal saline group | ? | 12 | 7.02±3.18 | - |
| Oleum Blumeae Balsamiferae eye drop group | 1.5 | 12 | 2.26±1.77 | 67.8％ |
| Oleum Blumeae Balsamiferae eye drop group | 0.15 | 12 | 3.81±2.63 | 45.7％ |
| Oleum Blumeae Balsamiferae eye drop group | 0.015 | 12 | 5.14±2.82 | 26.8％ |
Oleum Blumeae Balsamiferae eye drop therapeutic effect is remarkable, with matched group comparison, and P<0.01, difference has statistical significance.
By extracorporeal bacteria inhibitor test, irritation test, the antiinflammatory test experimental result of Oleum Blumeae Balsamiferae ophthalmic preparation, the effective dosage that can infer Oleum Blumeae Balsamiferae ophthalmic preparation is 0.15%～1%.
Test 4: the accelerated stability test of Oleum Blumeae Balsamiferae ophthalmic preparation
Get the sample that embodiment 1,4,6,8 makes, numbered samples 1,4,6,8, is placed on 40 ℃ ± 2 ℃ of temperature, in the incubator of relative humidity 75% ± 5%, by 1,2,3, check June.
Result: the color of sample, clarity and pH value, content does not all change.
The stable case of table 5 sample in accelerated test three months
This product microbial limit test of drugs meets the related microorganisms limit standard in version pharmacopeia in 2010, and product indicia thing content all, in acceptability limit, shows that product is stable.
Claims (13)
1. an Oleum Blumeae Balsamiferae ophthalmic preparation, is characterized in that the weight proportion of supplementary material component is: Oleum Blumeae Balsamiferae 0.15%～1%, all the other are adjuvant.
2. Oleum Blumeae Balsamiferae ophthalmic preparation according to claim 1, is characterized in that the weight proportion of raw material components is: Oleum Blumeae Balsamiferae 0.5%, all the other are adjuvant.
3. Oleum Blumeae Balsamiferae ophthalmic preparation according to claim 1 and 2, is characterized in that described ophthalmic preparation is ordinary eye drops, eye ointment, liposome, clathrate eye drop for eye.
4. an Oleum Blumeae Balsamiferae eye drop, is characterized in that being made by following percentage by weight raw material:
5. an Oleum Blumeae Balsamiferae liposome, is characterized in that being made by following percentage by weight raw material:
6. an Oleum Blumeae Balsamiferae eye ointment, is characterized in that being made by following percentage by weight raw material:
7. a Herba Blumeae Balsamiferae oilhole inclusion compound eye drops, is characterized in that being made by following percentage by weight raw material:
8. the Oleum Blumeae Balsamiferae ophthalmic preparation as described in claim 4-7 any one, is characterized in that:
Described cosolvent is one or more in Polyethylene Glycol, sodium benzoate, acetamide, hyaluronic acid sodium, carbomer, poloxamer, polyvinylpyrrolidone and sodium alginate;
Described antiseptic is one or more in benzalkonium bromide, ethyl hydroxybenzoate, ethyl hydroxybenzoate, phenethanol;
Described antioxidant is one or more in sodium sulfite, sodium sulfite and sodium pyrosulfite, sodium thiosulfate, disodiumedetate (EDTA), arabo-ascorbic acid and sodium salt thereof, thiourea.
9. the Oleum Blumeae Balsamiferae ophthalmic preparation as described in claim 4,5,7 any one, is characterized in that:
Described pH adjusting agent is one or more of sodium hydroxide, organic amine and/or mineral acid and salt, organic acid and salt thereof, sodium carbonate, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate, boric acid, Borax;
Described isoosmotic adjusting agent is one or more in sodium oxide, glucose, sodium acetate, sodium carbonate, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate, boric acid, Borax, propylene glycol, glycerol mannitol.
10. Oleum Blumeae Balsamiferae ophthalmic preparation as claimed in claim 5, is characterized in that:
Described eye is one or more in lecithin, PHOSPHATIDYL ETHANOLAMINE (PE), fabaceous lecithin, cholesterol, cephalin, cholesterol acetyl fat, cupreol, natrii tauroglycocholas, Yolk lecithin, synthetic two palmityls-DL-α phosphatidylcholine (DPPC), synthetic phospholipid acyl silk amino acid (PS), phosphatidylinositols (PI), sphingomyelin (SPH), sphingo (DCP), two myristoyl lecithin (DMPC), stearmide (SA) with liposome membrane material.
11. Oleum Blumeae Balsamiferae ophthalmic preparations as claimed in claim 6, is characterized in that:
Described eye pasting substrate is one or more in fatty alcohol, Yellow Vaselin, white vaseline, lanoline and white oil.
12. Oleum Blumeae Balsamiferae ophthalmic preparations as claimed in claim 7, is characterized in that:
The clathrate material of described clathrate eye drop is one or more of cyclodextrin (CD), beta-schardinger dextrin-(β-CD) and second-HP-β-CD (HP-β-CD).
The application of 13. Oleum Blumeae Balsamiferae ophthalmic preparations as described in claim 1-7 any one in preparation treatment infective conjunctivitis medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410335805.1A CN104127464B (en) | 2014-07-15 | 2014-07-15 | A kind of blumea oil eye-drops preparations and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410335805.1A CN104127464B (en) | 2014-07-15 | 2014-07-15 | A kind of blumea oil eye-drops preparations and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104127464A true CN104127464A (en) | 2014-11-05 |
| CN104127464B CN104127464B (en) | 2017-06-13 |
Family
ID=51800486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410335805.1A Active CN104127464B (en) | 2014-07-15 | 2014-07-15 | A kind of blumea oil eye-drops preparations and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104127464B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105267978A (en) * | 2015-11-12 | 2016-01-27 | 中国热带农业科学院热带作物品种资源研究所 | Preparation method and application of cyclodextrin inclusion compound containing Blumea balsamifera extract |
| CN107157923A (en) * | 2017-07-03 | 2017-09-15 | 武汉瑞福宁科技有限公司 | A kind of zoopery protection eye ointment and its application device |
| CN109674997A (en) * | 2019-01-02 | 2019-04-26 | 广东分子态生物股份有限公司 | A kind of transdermal absorbing composition containing Herba Blumeae Balsamiferae extract |
| CN110974861A (en) * | 2019-12-24 | 2020-04-10 | 贵州大学 | Blumea balsamifera oil liposome |
| CN113318036A (en) * | 2021-06-30 | 2021-08-31 | 花安堂生物科技集团有限公司 | New application of artemisia plant extract water |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488688A (en) * | 2011-12-05 | 2012-06-13 | 昆明振华制药厂有限公司 | Ophthalmic preparation by taking fibrauretinumrecisapierre as main drug |
-
2014
- 2014-07-15 CN CN201410335805.1A patent/CN104127464B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488688A (en) * | 2011-12-05 | 2012-06-13 | 昆明振华制药厂有限公司 | Ophthalmic preparation by taking fibrauretinumrecisapierre as main drug |
Non-Patent Citations (2)
| Title |
|---|
| 师琴丽等: "贵州优势苗药艾纳香及其产品", 《2003全国苗医药学术研讨会特辑》 * |
| 方灿等: "气相色谱法测定艾纳香油中左旋龙脑的含量", 《中国医院药学杂志》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105267978A (en) * | 2015-11-12 | 2016-01-27 | 中国热带农业科学院热带作物品种资源研究所 | Preparation method and application of cyclodextrin inclusion compound containing Blumea balsamifera extract |
| CN105267978B (en) * | 2015-11-12 | 2018-12-04 | 中国热带农业科学院热带作物品种资源研究所 | A kind of preparation method and applications of the cyclodextrin inclusion compound containing Herba Blumeae Balsamiferae extract |
| CN107157923A (en) * | 2017-07-03 | 2017-09-15 | 武汉瑞福宁科技有限公司 | A kind of zoopery protection eye ointment and its application device |
| CN109674997A (en) * | 2019-01-02 | 2019-04-26 | 广东分子态生物股份有限公司 | A kind of transdermal absorbing composition containing Herba Blumeae Balsamiferae extract |
| CN110974861A (en) * | 2019-12-24 | 2020-04-10 | 贵州大学 | Blumea balsamifera oil liposome |
| CN110974861B (en) * | 2019-12-24 | 2022-02-01 | 贵州大学 | Blumea balsamifera oil liposome |
| CN113318036A (en) * | 2021-06-30 | 2021-08-31 | 花安堂生物科技集团有限公司 | New application of artemisia plant extract water |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104127464B (en) | 2017-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103285028B (en) | Composite antibacterial agent of chitosan and organosilicone quaternary ammonium salt and preparation method of composite antibacterial agent | |
| CN104127464A (en) | Ophthalmic Blumea balsamifera oil preparation and preparation method thereof | |
| CN109288816B (en) | A kind of chloroquine gel and its preparation method and application | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN100413499C (en) | A nanoemulsion medicine of eugenol and preparation method thereof | |
| CN102836367B (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| CN103340965B (en) | External pharmaceutical composition used for treating skin diseases like eczema, dermatitis and tinea and preparation method thereof | |
| CN103130865A (en) | Sophocarpidine, oxymatrine glycyrrhetinic acid double salt, and preparation method and use thereof | |
| CN108404111B (en) | A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient | |
| CN104069124B (en) | Compositions and preparation for gynecological infection | |
| CN106581051A (en) | Nano microemulsion iodine and preparation method thereof | |
| CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
| CN101732244B (en) | Nose drops taking fibrauretine as main medicine and preparation method | |
| CN111905058A (en) | Pharmaceutical composition for skin mucosa nursing and wound repair and preparation method thereof | |
| CN110269839A (en) | A kind of application of cannabidiol CBD and its nano-emulsion in nettle rash or/and preparation for treating rhinitis | |
| CN103271842B (en) | Infant skin care oil containing prinsepia utilis rogle oil and preparation method thereof | |
| CN102488688A (en) | Ophthalmic preparation by taking fibrauretinumrecisapierre as main drug | |
| CN108785374A (en) | Faint scent cassia bark skin bacteriostatic gel and preparation method thereof | |
| CN106265720A (en) | A kind of combined artificial tear and preparation method thereof | |
| CN105228631A (en) | Comprise the topical formulations of hyaluronic acid, verbascoside and phosphoglycerol inositol | |
| CN104274391B (en) | Rifaximin-containing pharmaceutical preparation | |
| CN108079050A (en) | Herbal skin bacteria inhibiting composition and preparation method and application | |
| CN101342167B (en) | Medicament composition | |
| CN108066278B (en) | Gynecological gel containing chitosan oligosaccharide and preparation method thereof | |
| CN109954003B (en) | Nereid semen cytoplasm essence and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |